SRSF1 and healthy aging

Plesa and colleagues reported cellular aging-associated changes and, in an inducible aged-mouse study, 44% lower frailty progression and a 14% increase in median lifespan. The mouse groups were small (approximately 9–10 animals per group). These are preclinical results, not evidence of human benefit or safety. Read the Nature Aging paper.

What the public-data reanalysis shows

We compared the SRSF1-transgene condition with mTagBFP2/BFP controls at 2,000 ng/mL doxycycline for three days. The 24 selected columns represent two technical replicates per group across six donor lines. Technical replicates were averaged; donor line was treated as the independent unit. SampleID aliases were mapped directly from Supplementary Table 15, sheet 3a, to count-matrix columns and each selected alias matched exactly one GEO sample.

The authors' values come from Supplementary Table 15, sheet 3e. The OERSI values are exploratory log2(CPM + 0.5) estimates on the mapped 24-sample subset, not a replacement for DESeq2. Differences are expected because the estimators and subsets differ.

Two critical interpretation and safety issues

1. SRSF1 RNA is not total SRSF1 protein

Gene-level SRSF1 RNA is approximately 0.071× in the authors' DESeq2 table and 0.072× in our CPM calculation. This does not show that total SRSF1 protein fell or that the transgene failed. SRSF1 has negative autoregulatory splicing; ectopic cDNA expression can suppress endogenous transcript production. RNA abundance, transgene protein and total functional activity are different measures. See Sun et al. 2010 and Cell Reports 2022.

2. Oncogenic context matters

A 2023 Cancer Discovery study reported that increased SRSF1 can promote pancreatitis and accelerate KRAS^G12D-driven pancreatic cancer in a specific experimental context involving IL1R1/MAPK signalling. This does not prove that the fibroblast intervention causes cancer or that SRSF1 is generally unsafe. It makes tissue, dose, time and oncogenic background mandatory safety variables. Read the study.

The CXCL8 signal is one transcript in one induction condition. It should be reconciled with the original paper's broader report of reduced inflammatory signalling using protein and functional assays, not treated as a refutation of the whole paper.

Research path for OERSI

1. Reanalyse the full public dose/time series with explicit sample alias mapping, batch-aware count modelling and isoform-level analysis.
2. Pre-register comparisons, primary endpoints, exclusions and statistical thresholds before further condition analysis.
3. In independent cell systems, measure SRSF1 protein and isoforms, secreted IL-8/CXCL8, p21/p16 proteins, viability, proliferation and functional senescence readouts.
4. Compare multiple donor lines and tissue contexts; stratify or separately test KRAS/MYC backgrounds under appropriate biosafety and ethics review.
5. Advance only after independent replication and a reproducible separation between desired aging-associated outcomes and adverse stress/oncogenic signals.

Success is not “SRSF1 went up.” Success is a pre-specified and independently replicated benefit signal without unacceptable inflammatory, stress, proliferative or oncogenic effects in the contexts being tested.

Limitations, conflicts and evidence status

• Same originating preclinical dataset; no independent biological replication by OERSI.
• Six donor-derived fibroblast lines, one Dox dose and one 3-day induction schedule in this subset.
• The OERSI panel and sign tests are exploratory; six donors provide limited power and the sign tests have no multiple-testing correction.
• No full transcriptome/isoform, protein, secreted cytokine, functional senescence, tumour or clinical assessment was conducted here.
• The primary paper discloses patent interests (US20250313599A1) and RegulaBio founding/equity interests for named authors. This is material context for independent replication, not proof that the results are invalid.

No treatment, gene therapy, human intervention or self-experimentation is recommended or supported by this report.

Raw counts: GEO GSE325735. Supplementary sample mapping and authors' DESeq2 table: official article supplementary materials. This report does not mirror raw count data or the publisher's workbook.

References

1. Plesa AM et al. “Transcriptomic reprogramming screen identifies SRSF1 as a regulator of aging.” Nature Aging (2026). DOI 10.1038/s43587-026-01234-8.
2. GEO. GSE325735 public RNA-seq series.
3. Wan L et al. “Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer.” Cancer Discovery (2023). PMCID PMC10330071.
4. Sun S et al. SRSF1/SF2-ASF autoregulation. Nature Structural & Molecular Biology (2010). PMID 20139984.
5. “Dynamics and functional roles of splicing factor autoregulation.” Cell Reports (2022). DOI 10.1016/j.celrep.2022.110985.